Patients who are admitted to hospital with serious infections, such as those in bone, joints
or spine, require a long course of intravenous (IV) antibiotics. After an initial treatment
course in hospital or through a dedicated outpatient antibiotic program many patients can
complete their treatment course at home. Such infections are often caused by bacteria called
Staphylococci, and currently there are three antibiotic options used routinely. A fourth
antibiotic, ceftriaxone, is a promising alternative; it is also effective against
Staphylococci, and is more convenient, less costly and easier to give at home, however, it
has not been studied thoroughly in a prospective manner. This study will compare ceftriaxone
to routinely used antibiotics (cloxacillin, cefazolin or daptomycin) to see if ceftriaxone is
equally as safe and efficacious in curing deep-seated Staphylococcal infections in patients
receiving home IV antibiotics. Patients with deep-seated infections caused by
methicillin-susceptible Staphylococcus aureus (MSSA) or coagulase-negative Staphylococcal
species will be randomly assigned home IV treatment with ceftriaxone OR one of the three
other antibiotics before leaving the hospital. Patients will then receive usual care from an
Infectious Disease physician and Home IV team. The study team will assess whether cure has
been achieved by the end of the IV treatment, follow-up at 6 months to see if patients remain
infection-free, and record any side-effects of treatment. The overall goal is to determine
whether ceftriaxone can be considered non-inferior to usual antibiotic treatment in treating
Staphylococcal infections in a home IV setting.